Cbl proto-oncogene, E3 ubiquitin protein ligase

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help


Alternate Names:  CBL2; oncogene CBL2
Alternate Symbols:  RNF55; c-Cbl
PharmGKB Accession Id: PA26115


Cytogenetic Location: chr11 : q23.3 - q23.3
GP mRNA Boundary: chr11 : 119076986 - 119178859
GP Gene Boundary: chr11 : 119066986 - 119181859
Strand: plus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. cbl mediated ligand-induced downregulation of egf receptors pathway - (BioCarta via Pathway Interaction Database)
  2. EGFR downregulation - (Reactome via Pathway Interaction Database)
  3. EPHA forward signaling - (Pathway Interaction Database NCI-Nature Curated)
  4. EPHA2 forward signaling - (Pathway Interaction Database NCI-Nature Curated)
  5. EPO signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  6. FGF signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  7. IFN-gamma pathway - (Pathway Interaction Database NCI-Nature Curated)
  8. il-2 receptor beta chain in t cell activation - (BioCarta via Pathway Interaction Database)
  9. IL4-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  10. Insulin Pathway - (Pathway Interaction Database NCI-Nature Curated)
  11. Integrins in angiogenesis - (Pathway Interaction Database NCI-Nature Curated)
  12. Paxillin-dependent events mediated by a4b1 - (Pathway Interaction Database NCI-Nature Curated)
  13. Paxillin-independent events mediated by a4b1 and a4b7 - (Pathway Interaction Database NCI-Nature Curated)
  14. PDGFR-beta signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  15. Reelin signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  16. Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met) - (Pathway Interaction Database NCI-Nature Curated)
  17. Signaling events mediated by Stem cell factor receptor (c-Kit) - (Pathway Interaction Database NCI-Nature Curated)
  18. sprouty regulation of tyrosine kinase signals - (BioCarta via Pathway Interaction Database)
  19. TCR signaling in naïve CD4+ T cells - (Pathway Interaction Database NCI-Nature Curated)
  20. TCR signaling in naïve CD8+ T cells - (Pathway Interaction Database NCI-Nature Curated)
  21. VEGFR1 specific signals - (Pathway Interaction Database NCI-Nature Curated)

Publications related to CBL: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. Annals of laboratory medicine. 2015. Park Sang Hyuk, et al. PubMed


NCBI Gene:
UCSC Genome Browser:
RefSeq RNA:
RefSeq Protein:
RefSeq DNA:
CBL_HUMAN (P22681)
Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches